William Lis - 13 Oct 2023 Form 4 Insider Report for Jasper Therapeutics, Inc. (JSPR)

Reporting relationship: Director
Issuer ticker: JSPR
Reported as of: 13 Oct 2023
Net transaction value: -$6,777
SEC form: 4
Accepted by SEC: 13 Oct 2023, 18:56:56 UTC
Prior SEC filing: 30 Jun 2023
Next SEC filing: 20 Jun 2024
Source filing: View source filing
Reporting owner signature: By: /s/ Jeet Mahal, as Attorney-in-Fact

Key filing fact

William Lis filed Form 4 for Jasper Therapeutics, Inc. (JSPR) on 13 Oct 2023.

Key facts

This page summarizes William Lis's Form 4 filing for Jasper Therapeutics, Inc. (JSPR).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 13 Oct 2023, 18:56.

Change

Previous filing in this sequence was filed on 30 Jun 2023.
Current net transaction value: -$6,777.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

JSPR transaction

Voting Common Stock

Sale

Transaction value: $6,777
Shares: -7,965
Change %: -13%
Price: $0.8508
Shares after: 53,521
Date: 13 Oct 2023
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

The transaction reported in this Form 4 was effected pursuant to a trading plan intended to comply with Rule 10b5-1(c) and adopted by the Reporting Person on June 15, 2023.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.84 to $0.8717, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price.